This Neuroscience Center Core Facility, directed by Drs. Xandra Breakefield and Bakhos Tannous will be an institutionally unique resource which will bring our neuroscience faculty together and enhance their research on neurologic disorders through powerful, synergistic new technologies. The three new proposed cores are truly state-of-the-art. The Imaging Core (directed by Drs. Brad Hyman and Marian DiFiglia) will include array tomography, transmission electron microscopy and in vivo multiphoton imaging of detailed brain structure. The Microfluidics Core (directed by Drs. Daniel Irimia and Mehmet Toner) will provide specialized microfluidic devices and expertise in analysis for separation of cells and cell organelles, and high precision, real-time imaging of cell migration and axon guidance. The Vector Core (directed by Drs. Bakhos Tannous and Xandra Breakefield) will generate a variety of viral vectors for all projects and continue to expand its repertoire with advances in this field now including 10 serotypes of adeno-associated virus (AAV) vectors and coat-deficient rabies virus. The administration organization overseeing this program will include the P30 Director/Co-Director and Core Directors/Co-Directors to monitor ongoing activities and to interface with users; a Steering Committee to review operating procedures and activity reports on an annual basis, and to advise on prioritization issues and core effectiveness; an Advisory Board to offer advice on technology updates and management issues; and an Administrative Core which will logistically support the program with a dedicated senior grants manager All these services will be offered free-of-charge to the NINDS-funded neuroscience investigators at our institution and will serve to create a very dynamic, interactive environment where ideas become reality. This group of neuroscience investigators includes international leaders in the field, as well as junior and mid-level investigators for whom research on neurologic disorders is the main focus of their work and who have made many major contributions in the field. Our research covers a broad range of neurologic disorders due to stroke, injury, brain tumors and seizures, as well as neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and Huntington's disease, and pediatric disorders, such as early onset dystonia, familial dysautonomia, hereditary sensory and autonomic neuropathy and adrenoleukodystrophy. Our vision for this PSO Core Facility is to achieve a deeper level of understanding of disease pathogenesis and to discover means of alleviation by providing technologies which can achieve high resolution of brain structure.

Public Health Relevance

Our program will support basic and translational research on a large number of neurologic disorders which have devastating on humans. The availability of the proposed high resolution technologies will be critical in elucidating the molecular and cellula etiologies of these disorders. In a hospital setting we are well positioned to translate our findins into improved diagnosis and therapy, and have a strong track record in improving patient care in neurologic disorders through research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Center Core Grants (P30)
Project #
2P30NS045776-11A1
Application #
8662508
Study Section
Special Emphasis Panel (ZNS1-SRB-B (38))
Program Officer
Stewart, Randall R
Project Start
2003-05-01
Project End
2018-11-30
Budget Start
2015-01-15
Budget End
2015-11-30
Support Year
11
Fiscal Year
2015
Total Cost
$690,198
Indirect Cost
$290,198
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Pagnier, Guillaume J; Kastanenka, Ksenia V; Sohn, Miwon et al. (2018) Novel botanical drug DA-9803 prevents deficits in Alzheimer's mouse models. Alzheimers Res Ther 10:11
Jorfi, Mehdi; D'Avanzo, Carla; Kim, Doo Yeon et al. (2018) Three-Dimensional Models of the Human Brain Development and Diseases. Adv Healthc Mater 7:
Landeira, Bruna Soares; Santana, Themis Taynah da Silva; Araújo, Jéssica Alves de Medeiros et al. (2018) Activity-Independent Effects of CREB on Neuronal Survival and Differentiation during Mouse Cerebral Cortex Development. Cereb Cortex 28:538-548
György, Bence; Cruz, Lilian; Yellen, David et al. (2018) Mutant torsinA in the heterozygous DYT1 state compromises HSV propagation in infected neurons and fibroblasts. Sci Rep 8:2324
DeVos, Sarah L; Corjuc, Bianca T; Commins, Caitlin et al. (2018) Tau reduction in the presence of amyloid-? prevents tau pathology and neuronal death in vivo. Brain 141:2194-2212
Teng, Jian; Hejazi, Seyedali; Hiddingh, Lotte et al. (2018) Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro Oncol 20:642-654
Kovalenko, Marina; Milnerwood, Austen; Giordano, James et al. (2018) HttQ111/+ Huntington's Disease Knock-in Mice Exhibit Brain Region-Specific Morphological Changes and Synaptic Dysfunction. J Huntingtons Dis 7:17-33
Jorfi, Mehdi; D'Avanzo, Carla; Tanzi, Rudolph E et al. (2018) Human Neurospheroid Arrays for In Vitro Studies of Alzheimer's Disease. Sci Rep 8:2450
Arbel-Ornath, Michal; Hudry, Eloise; Boivin, Josiah R et al. (2017) Soluble oligomeric amyloid-? induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Mol Neurodegener 12:27
Teng, Jian; Carla da Hora, Cintia; Kantar, Rami S et al. (2017) Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro Oncol 19:820-832

Showing the most recent 10 out of 147 publications